SCHEMBL30765624

SCHEMBL30765624

O=C(Cn1c(-c2ccccc2)ncc(NC(=O)c2ccc(-c3ccccc3)cc2F)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.42
NTRK1 P04629 2/20 0.41
NTRK3 Q16288 1/20 0.40
ELANE P08246 5/20 0.40
CMA1 P23946 4/20 0.38
CTRC Q99895 4/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ITGB1 P05556 1/20 0.36
ITGAV P06756 1/20 0.36
ITGA5 P08648 1/20 0.36
ITGB8 P26012 1/20 0.36
HDAC1 Q13547 1/20 0.36
GHSR Q92847 2/20 0.36
F3 P13726 1/20 0.36
ROCK2 O75116 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558568 0.89 NTRK1 (0.45) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30766049 0.84 NTRK1 (0.43) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765697 0.83 F2 (0.43) CASP1NTRK1NTRK3ELANECMA1
Hydrochloric Acid SCHEMBL30765434 0.83 NTRK1 (0.43) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765974 0.83 CASP1 (0.44) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30766005 0.83 CASP1 (0.41) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765851 0.83 NTRK1 (0.40) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765954 0.83 HDAC1 (0.40) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30765732 0.82 NTRK1 (0.40) CASP1NTRK1NTRK3ELANECMA1
SCHEMBL30766050 0.82 ELANE (0.41) CASP1NTRK1NTRK3ELANECMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed